Abstract | BACKGROUND: METHODS: 86 patients, admitted within initial 12 h of the first STEMI. Admission plasma levels of BNP were measured by MEIA method. Serum levels of CRP were measured using immunoturbidimetric assays. Composite end point (CEP) was assessed after 7 months. RESULTS: Median plasma BNP value was higher in patients with CEP, compared with those without CEP (p<0.001). Patients with plasma BNP >99.2 pg/mL were at significantly higher risk for CEP (the highest sensitivity and specificity). CRP level >10.6 mg/dL was also associated with poor outcome. TRS has not influenced the occurrence of CEP. In the analysis of logistic regression the BNP value >99.2 pg/mL was the strongest predictor of CEP. ROC analysis identified BNP measurement as significant to estimate adverse outcome 0.950 in the prediction of CEP (95% Confidence interval=0.878-0.985). CONCLUSION: Admission plasma BNP concentrations provide incremental prognostic information in patients with first STEMI treated with pPCI.
|
Authors | Agnieszka M Kuklinska, Bozena Sobkowicz, Barbara Mroczko, Robert Sawicki, Wlodzimierz J Musial, Malgorzata Knapp, Slawomir Dobrzycki, Maciej Szmitkowski |
Journal | Clinica chimica acta; international journal of clinical chemistry
(Clin Chim Acta)
Vol. 382
Issue 1-2
Pg. 106-11
(Jul 2007)
ISSN: 0009-8981 [Print] Netherlands |
PMID | 17482153
(Publication Type: Comparative Study, Journal Article)
|
Chemical References |
- Natriuretic Peptide, Brain
- C-Reactive Protein
|
Topics |
- Aged
- Angioplasty, Balloon, Coronary
- Arrhythmias, Cardiac
- C-Reactive Protein
(analysis, metabolism)
- Female
- Humans
- Male
- Middle Aged
- Myocardial Infarction
(blood, physiopathology, therapy)
- Natriuretic Peptide, Brain
(blood)
- Predictive Value of Tests
- Prognosis
- Prospective Studies
- ROC Curve
- Risk Assessment
- Severity of Illness Index
|